Hematopoiesis is the most thoroughly characterized cell renewal, proliferation and differentiation system in biology. A central dogma is that the system is hierarchical with an orderly progression from stem cell to progenitor cell to differentiated end cell involving a progressive loss of proliferative potential linked to a gain of differentiated characteristics. A second dogma is that myeloablated treatment with radiation or chemotherapy is necessary to 'open space' in order for the transfused stem cells to engraft in marrow. A third dogma is that lymphohematopoietic stem cell is in G 0 or quiescent and that it is difficult to induce this cell to enter cell cycle and divide. These three dogmas appear to be incorrect as developed below.
(1) Marrow 'space' needs to be created to allow transplanted stem cells to engraft. ( 2) The stem cell is quiescent and it is difficult to stimulate it to proliferate. (3) The stem cell phenotype is stable within a differentiation hierarchy.
Marrow space
Following on the work of others, [1] [2] [3] we have shown that virtually quantitative engraftment occurs when male BALB/c marrow cells are infused into female BALB/c hosts which have received no myeloablative treatment. [4] [5] [6] [7] [8] In this model, male cells are tracked by Southern blot or fish using Y-specific probes and the percent of male cells in female marrow, spleen or thymus determined at varying time points after marrow cell infusion. We have shown stable multilineage engraftment out to over 2 years post infusion of 200 million male BALB/c cells into female BALB/c hosts. We have shown that there is a cell dose response and that the engrafting stem cell in this model is quiescent as determined by hydroxyurea suicide. The explanation of these results appears to be based upon stem cell competition. The final engraftment phenotype would appear to be determined solely by the ratio of host to donor stem cells, rather than any treatment 'opening space'. We have extended these results to a minimally myeloablated model in which low doses of irradiation are administered and engraftment evaluated. 9 In this model, 100 cGy whole body irradiation causes mild, albeit significant, depressions of the peripheral blood platelet and white count, which recover over 2 weeks, without significant changes in marrow cellularity. These relatively mild effects are contrasted with the severe inhibition of long-term stem cell engraftment. When male BALB/c marrow cells are exposed to 100 cGy in vitro or in vivo and then evaluated 2 months after engraftment, they lose over 80% of their engrafting ability. Using this model and engrafting 40 million male cells into 100 cGy exposed mice we have shown very high levels of chimerism at times approaching 100% at 2, 5 and 8 months post engraftment. The engrafting cells here are also quiescent. These data further substantiate the hypothesis that the final phenotype after marrow cell engraftment is determined by ratios of host to donor stem cells, rather than other phenomenology.
Quiescence of the stem cell
As noted above, in our initial studies, the stem cell engrafting in nonmyeloablated hosts (and in myeloablated hosts) is quiescent as determined by hydroxyurea suicide techniques. Hydroxyurea kills cells traversing S and thus gives a measure of the proliferative status of a cell population. We have evaluated the cycling status of cells after engraftment into nonmyeloablated mice by administering hydroxyurea at 0, 3, 12 and 15 h post engraftment. 10 Engraftment was then analyzed 6 weeks after marrow infusion. There is no effect of hydroxyurea at 0, 3 and 15 h but a marked reduction in generated donor cells in peripheral blood and marrow at 6 weeks when hydroxyurea was administered at 12 h indicating that the bulk of cells had entered cell cycle within this time interval. Hendrix and colleagues 11 have similar data suggesting that engrafted syngeneic cells have progressed through cycle in the first 1-2 days of engraftment. Thus, our own data and that of others indicates that primitive long-term engrafting stem cells, rather than being difficult to induce into cell cycle, are easily induced into cell cycle. This is further supported by in vitro studies using the cytokine combination of IL-3, IL-6, IL-11 and steel factor in which highly purified lineage negative Rho low Ho low cells progress from dormancy (or G 0 ) to the first mitosis by 40 h. This relatively long first cycle is followed by rapid 12 h cycles. Thus, both in vitro and in vivo primitive stem cells appear to be easily induced into stem cell.
The phenotype of the primitive engrafting stem cell is stable within a hierarchical differentiation system
In the studies described above, incubating male BALB/c marrow cells in IL-3, IL-6, IL-11 and steel factor, we have found an expansion of high proliferative colony-forming cells and total colony-forming cells at 48 h of culture. This was discordant with the observations on engrafting stem cells. The longterm engrafting potential of stem cells after 48 h of culture was markedly decreased. 12, 13 A major question was whether this defective engraftment represented a permanent differentiation event, or whether this was a plastic reversible change, potentially associated with cell cycle transit. Studies on the engraftment potential of cells in this cytokine cocktail over 24-48 h have now shown that the cells appear to develop an engraftment defect in late S or G 2 of recurrent cycles indicating the plastic nature of the engraftable stem cell.
These data suggest that the phenotype of the hematopoietic stem cell alters during cell cycle transit and that part of the regulatory system of hematopoiesis is cell cycle rather than hierarchically based. These studies have major implications for gene therapy strategies in which retroviral vectors are incorporated into proliferating cells. Many of the failures of gene therapy may in fact be due to defective engraftment as opposed to the basic nature of the vectors utilized. In addition, these studies indicate that with relatively nontoxic therapy, bone marrow chimeric states can be created which might form a base for approaches to the creation of allochimeric models in nonmalignant marrow states such as sickle cell anemia and thalassemia. Here, the major goal would be to develop approaches to create tolerance and modulate graftversus-host disease and graft rejection. Finally, in order to maximize any therapeutic effect of cytokine-treated stem cells in vitro, strategies must include an understanding of the cell cycle status and engraftment potential of these cells at different points in cell cycle.
